Identification of hsa_circRNA_100632 as a novel molecular biomarker for fulminant type 1 diabetes

ObjectiveCircular RNAs (circRNAs) are associated with diabetes, but their role in fulminant type 1 diabetes (FT1D) is unclear. Thus, we characterized the role of circRNAs in FT1D.Research design and methodsCircRNA expression profiles were detected in peripheral blood mononuclear cells (PBMCs) of fiv...

Full description

Bibliographic Details
Main Authors: Wenfeng Yin, Shuoming Luo, Junlin Qiu, Zilin Xiao, Ziwei Zhang, Zhiguo Xie, Xia Li, Zhiguang Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1075970/full
_version_ 1797896052712407040
author Wenfeng Yin
Shuoming Luo
Junlin Qiu
Zilin Xiao
Ziwei Zhang
Zhiguo Xie
Xia Li
Zhiguang Zhou
author_facet Wenfeng Yin
Shuoming Luo
Junlin Qiu
Zilin Xiao
Ziwei Zhang
Zhiguo Xie
Xia Li
Zhiguang Zhou
author_sort Wenfeng Yin
collection DOAJ
description ObjectiveCircular RNAs (circRNAs) are associated with diabetes, but their role in fulminant type 1 diabetes (FT1D) is unclear. Thus, we characterized the role of circRNAs in FT1D.Research design and methodsCircRNA expression profiles were detected in peripheral blood mononuclear cells (PBMCs) of five FT1D patients and five controls using a circRNA microarray. An independent cohort comprised of 40 FT1D cases, 75 type 1 diabetes (T1D) cases, and 115 controls was used to verify the circRNAs using quantitative real-time polymerase chain reaction (qRT-PCR). Spearman’s correlation analysis and receiver operating characteristic (ROC) curve analysis were performed to determine the clinical diagnostic capability of circRNAs. Bioinformatics was used to identify potential biological functions and circRNA–miRNA–mRNA interactions.ResultsThere were 13 upregulated and 13 downregulated circRNAs in PBMCs of patients with FT1D. Five circRNAs were further verified in a second cohort. Hsa_circRNA_100632 was significantly upregulated in the FT1D and T1D groups. Hsa_circRNA_100632 was differentiated between patients with FT1D and controls [area under the curve (AUC) 0.846; 95% CI 0.776–0.916; P<0.0001] as well as between patients with FT1D and patients with T1D (AUC 0.726; 95% CI 0.633–0.820; P<0.0001). Bioinformatics analysis showed that hsa_circRNA_100632 may be involved in 47 circRNA–miRNA–mRNA signaling pathways associated with diabetes.ConclusionsCircRNAs were aberrantly expressed in PBMCs of patients with FT1D, and hsa_circRNA_100632 may be a diagnostic marker of FT1D.
first_indexed 2024-04-10T07:36:43Z
format Article
id doaj.art-7386e804eb9e42e0b63d3b283817e384
institution Directory Open Access Journal
issn 1664-3224
language English
last_indexed 2024-04-10T07:36:43Z
publishDate 2023-02-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj.art-7386e804eb9e42e0b63d3b283817e3842023-02-23T12:39:53ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-02-011410.3389/fimmu.2023.10759701075970Identification of hsa_circRNA_100632 as a novel molecular biomarker for fulminant type 1 diabetesWenfeng YinShuoming LuoJunlin QiuZilin XiaoZiwei ZhangZhiguo XieXia LiZhiguang ZhouObjectiveCircular RNAs (circRNAs) are associated with diabetes, but their role in fulminant type 1 diabetes (FT1D) is unclear. Thus, we characterized the role of circRNAs in FT1D.Research design and methodsCircRNA expression profiles were detected in peripheral blood mononuclear cells (PBMCs) of five FT1D patients and five controls using a circRNA microarray. An independent cohort comprised of 40 FT1D cases, 75 type 1 diabetes (T1D) cases, and 115 controls was used to verify the circRNAs using quantitative real-time polymerase chain reaction (qRT-PCR). Spearman’s correlation analysis and receiver operating characteristic (ROC) curve analysis were performed to determine the clinical diagnostic capability of circRNAs. Bioinformatics was used to identify potential biological functions and circRNA–miRNA–mRNA interactions.ResultsThere were 13 upregulated and 13 downregulated circRNAs in PBMCs of patients with FT1D. Five circRNAs were further verified in a second cohort. Hsa_circRNA_100632 was significantly upregulated in the FT1D and T1D groups. Hsa_circRNA_100632 was differentiated between patients with FT1D and controls [area under the curve (AUC) 0.846; 95% CI 0.776–0.916; P<0.0001] as well as between patients with FT1D and patients with T1D (AUC 0.726; 95% CI 0.633–0.820; P<0.0001). Bioinformatics analysis showed that hsa_circRNA_100632 may be involved in 47 circRNA–miRNA–mRNA signaling pathways associated with diabetes.ConclusionsCircRNAs were aberrantly expressed in PBMCs of patients with FT1D, and hsa_circRNA_100632 may be a diagnostic marker of FT1D.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1075970/fullcircular RNAsfulminant type 1 diabetesbiomarkersdiagnostic evaluationimmune regulation
spellingShingle Wenfeng Yin
Shuoming Luo
Junlin Qiu
Zilin Xiao
Ziwei Zhang
Zhiguo Xie
Xia Li
Zhiguang Zhou
Identification of hsa_circRNA_100632 as a novel molecular biomarker for fulminant type 1 diabetes
Frontiers in Immunology
circular RNAs
fulminant type 1 diabetes
biomarkers
diagnostic evaluation
immune regulation
title Identification of hsa_circRNA_100632 as a novel molecular biomarker for fulminant type 1 diabetes
title_full Identification of hsa_circRNA_100632 as a novel molecular biomarker for fulminant type 1 diabetes
title_fullStr Identification of hsa_circRNA_100632 as a novel molecular biomarker for fulminant type 1 diabetes
title_full_unstemmed Identification of hsa_circRNA_100632 as a novel molecular biomarker for fulminant type 1 diabetes
title_short Identification of hsa_circRNA_100632 as a novel molecular biomarker for fulminant type 1 diabetes
title_sort identification of hsa circrna 100632 as a novel molecular biomarker for fulminant type 1 diabetes
topic circular RNAs
fulminant type 1 diabetes
biomarkers
diagnostic evaluation
immune regulation
url https://www.frontiersin.org/articles/10.3389/fimmu.2023.1075970/full
work_keys_str_mv AT wenfengyin identificationofhsacircrna100632asanovelmolecularbiomarkerforfulminanttype1diabetes
AT shuomingluo identificationofhsacircrna100632asanovelmolecularbiomarkerforfulminanttype1diabetes
AT junlinqiu identificationofhsacircrna100632asanovelmolecularbiomarkerforfulminanttype1diabetes
AT zilinxiao identificationofhsacircrna100632asanovelmolecularbiomarkerforfulminanttype1diabetes
AT ziweizhang identificationofhsacircrna100632asanovelmolecularbiomarkerforfulminanttype1diabetes
AT zhiguoxie identificationofhsacircrna100632asanovelmolecularbiomarkerforfulminanttype1diabetes
AT xiali identificationofhsacircrna100632asanovelmolecularbiomarkerforfulminanttype1diabetes
AT zhiguangzhou identificationofhsacircrna100632asanovelmolecularbiomarkerforfulminanttype1diabetes